Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
- 29 July 2003
- journal article
- clinical trial
- Published by Springer Nature in Diabetologia
- Vol. 46 (10) , 1319-1323
- https://doi.org/10.1007/s00125-003-1181-x
Abstract
Our aim was to investigate possible interaction between gemfibrozil and rosiglitazone, a thiazolidinedione antidiabetic drug.Keywords
This publication has 9 references indexed in Scilit:
- Absorption, Disposition, and Metabolism of Rosiglitazone, a Potent Thiazolidinedione Insulin Sensitizer, in HumansDrug Metabolism and Disposition, 2025
- Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinideDiabetologia, 2003
- Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver MicrosomesDrug Metabolism and Disposition, 2002
- Gemfibrozil greatly increases plasma concentrations of cerivastatinClinical Pharmacology & Therapeutics, 2002
- Thiazolidinedione‐Induced EdemaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepirideClinical Pharmacology & Therapeutics, 2001
- Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.2001
- Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazoneBritish Journal of Clinical Pharmacology, 1999